{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"6.0","upperLimit":"16.0","value":"9.1"},{"comment":"The upper confidence limit could not be determined due to the censoring.","groupId":"OG004","lowerLimit":"18.8","upperLimit":"NA","value":"35.8"},{"groupId":"OG005","lowerLimit":"10.8","upperLimit":"60.6","value":"25.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"39"}],"units":"Participants"}],"description":"Kaplan-Meier curves will be generated for OS stratified by histology; median OS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG000","title":"Phase I, All Histologies, Lenalidomide 15 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG001","title":"Phase I, All Histologies, Lenalidomide 20 mg"},{"description":"Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG002","title":"Phase I, All Histologies, Lenalidomide 25 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG003","title":"Phase II, Diffuse Large B-Cell Subtype"},{"description":"Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG004","title":"Phase II, Follicular Subtype"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"OG005","title":"Phase II, Lymphoma NOS"}],"paramType":"MEDIAN","populationDescription":"Only phase II patients were followed for overall survival.\n\nNote:999999 for the upper confidence interval of the median for the follicular subtype means \"not estimable.\"","reportingStatus":"POSTED","timeFrame":"Time from study entry until death from any cause, assessed up to 6 years","title":"Overall Survival (OS) (Phase II)","type":"SECONDARY","unitOfMeasure":"Months"}